|Day Low/High||44.09 / 45.93|
|52 Wk Low/High||24.75 / 79.90|
Cramer says don't buy Tesaro but do buy Cirrus Logic.
Cramer says discipline is needed to start trimming positions and taking profits.
Biotech stocks remain pressured following the recent Brexit vote, which will make investing in these already highly volatile stocks even trickier. But there are opportunities too.
- Data demonstrate that abaloparatide-SC reduced the risk of osteoporotic fractures and increased bone mineral density across a broad group of postmenopausal women with osteoporosis regardless of baseline characteristics -
Radius Health and Seres Therapeutics have something in common, Cramer says -- both are great biotechs being dragged down by the current market.
When it comes to the first quarter of 2016, it was the worst of times or it was the best of times, Cramer says
Cramer loves Bristol-Myers and he's not betting against Goldman Sachs.
There are many low-value stocks that never should've gotten that low in the first place, Cramer says.
Cantor Fitzgerald lowered its price target on Radius Health (RDUS) stock to reflect lower biotechnology valuations in the current market environment.
Radius Health (RDUS) stock is lower in pre-market trading on a ratings downgrade to 'hold' from 'buy' at Jefferies.
Here are Wednesday's top research calls, including downgrades for Ford and Macy's, an upgrade for Walmart and new coverage on AT&T.
Radius Health (RDUS) stock closed up today after Amgen (AMGN) reported data indicating that its osteoporosis drug didn't perform as well as Radius Health's.
Amgen and partner UCB intend to seek regulatory approval for the new osteoporosis drug, romosozumab, later this year.